Gemcitabine is a potential antitumoral agent used as a first-line drug for pancreatic cancer treatment, whereas HIF1α-siRNA can downregulate the HIF1-α, a heterodimer related to tumor cells’ survival in hypoxia conditions. The gene discussed is HIF1A; the disease is neoplasm.